Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Inlyta Articles

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28 March 2013

Advantages of Tivopath over currently used kidney cancer therapies seen by thought leaders

27 March 2013

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

9 January 2013

Pfizer's Inlyta misses primary endpoint in Ph III kidney cancer trial

18 October 2012

European approval for Pfizer's kidney cancer drug Inlyta

5 September 2012

Europe's CHMP issues positive opinions on aclidinium, Fycompa, Inlyta and NovoThirteen

27 May 2012

FDA OKs Pfizer’s Inlyta and accepts NDA for bosutinib

30 January 2012

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS